All News

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.

Data from DREAMM-7 and DREAMM-8 support the marketing authorization application for the belantamab mafodotin combinations in multiple myeloma.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.

Phase 1 data show that EMI-137 enabled MFGI and spectroscopy differentiation between papillary thyroid cancer–afflicted tissue and healthy thyroid tissue.

The drug developers of tabelecleucel are seeking approval of the treatment for patients with EBV-positive post-transplant lymphoproliferative disease.

The overall survival benefit seen with DOC1021 in a phase 1 trial of glioblastoma support the fast track status decision for the agent.

“The machine learning algorithms based on pure clinical data aren’t any better, [but] that’s where prostate cancer algorithms are starting to shine,” said James B. Yu, MD, MHS, FASTRO.

Developers plan to submit data from the ARANOTE trial to global regulatory health authorities to expand indications for darolutamide in metastatic HSPC.

The conundrum of treating dermatologic adverse effects in response to treatment with amivantamab for EGFR-mutated NSCLC was discussed in a recent Frontline Forum.

Retrospective results found considering conservative initial surgery options can reduce overtreatment for patients with thyroid cancer.

A serious grade 4 adverse effect reported in the phase 1/2 dose-escalation study evaluating seclidemstat combination therapy prompted the partial hold.

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

Laura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.

Phase 3 results show that treatment with vandetanib had no statistically significant improvement in PFS and more adverse effects than placebo.

Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.

The use of an ultrasensitive assay was able to detect HPV-16-positive SiHa cells at greater than 500 cells/mL for cervical cancer.

Approximately two-thirds of patients who received study treatment in NeoACTIVATE had no remaining tumors at the time of surgery.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

A panel of experts in multiple myeloma discussed strategies for sequencing novel bispecific antibodies and CAR T-cell therapies for patients with relapsed/refractory disease.

The results of the trial showed that at least 75% of patients with NSCLC harboring driver gene alterations may benefit from this treatment.

Experts in multiple myeloma discussed the evolving role of CAR T-cell therapy for patients with relapsed/refractory disease.

Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.

“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.